primaryid int64 82.9M 2.23B | caseid int64 8.29M 23.4M | caseversion int64 1 47 | i_f_code stringclasses 2
values | event_dt float64 20M 20.2M ⌀ | mfr_dt float64 20.2M 20.2M ⌀ | init_fda_dt stringdate 2011-12-14 00:00:00 2023-12-31 00:00:00 | fda_dt stringdate 2023-01-02 00:00:00 2023-12-31 00:00:00 | rept_cod stringclasses 5
values | auth_num stringclasses 98
values | mfr_num stringlengths 13 54 ⌀ | mfr_sndr stringclasses 138
values | lit_ref stringclasses 81
values | age float64 0 24.3k ⌀ | age_cod stringclasses 4
values | age_grp stringclasses 6
values | sex stringclasses 3
values | e_sub stringclasses 2
values | wt float64 2 245 ⌀ | wt_cod stringclasses 2
values | rept_dt stringdate 2022-12-21 00:00:00 2023-12-31 00:00:00 | to_mfr stringclasses 2
values | occp_cod stringclasses 5
values | reporter_country stringclasses 48
values | occr_country stringclasses 46
values | _quarter stringclasses 4
values | age_years float64 0 95 ⌀ | sex_label stringclasses 3
values | reporter_type stringclasses 5
values | report_type stringclasses 5
values | wt_kg float64 2 175 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
232,281,631 | 23,228,163 | 1 | I | 20,230,101 | 20,231,115 | 2023-11-25 | 2023-11-25 | PER | null | PR-ABBVIE-5507799 | ABBVIE | null | null | null | A | F | Y | null | null | 2023-11-25 | null | MD | PR | PR | 2023Q4 | null | Female | Physician | Periodic | null |
226,302,671 | 22,630,267 | 1 | I | null | null | 2023-06-19 | 2023-06-19 | DIR | FDA-CDER-CTU-2023-45191 | null | FDA-CTU | null | null | null | null | F | N | null | null | 2023-06-18 | N | HP | US | null | 2023Q2 | null | Female | Health professional | Direct | null |
228,798,591 | 22,879,859 | 1 | I | 20,220,801 | 20,220,826 | 2023-08-29 | 2023-08-29 | PER | null | US-PERRIGO-22US011907 | PERRIGO | null | null | null | null | F | Y | null | null | 2023-08-29 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Periodic | null |
226,160,421 | 22,616,042 | 1 | I | 20,230,519 | 20,230,609 | 2023-06-19 | 2023-06-19 | EXP | null | CN-BAYER-2023A082580 | BAYER | null | 59 | YR | A | F | Y | 57 | KG | 2023-06-19 | null | HP | CN | CN | 2023Q2 | 59 | Female | Health professional | Expedited | 57 |
230,380,651 | 23,038,065 | 1 | I | null | 20,231,003 | 2023-10-06 | 2023-10-06 | EXP | null | JP-BAYER-2023A139480 | BAYER | null | null | null | null | null | Y | null | null | 2023-10-06 | null | MD | JP | JP | 2023Q4 | null | Unknown | Physician | Expedited | null |
227,855,561 | 22,785,556 | 1 | I | 20,221,001 | 20,221,004 | 2023-08-04 | 2023-08-04 | PER | null | US-OTSUKA-2022_047605 | OTSUKA | null | 43 | YR | null | F | Y | 72.57 | KG | 2023-08-04 | null | CN | US | US | 2023Q3 | 43 | Female | Consumer | Periodic | 72.6 |
228,907,281 | 22,890,728 | 1 | I | null | 20,230,712 | 2023-09-01 | 2023-09-01 | EXP | null | US-ENDO-CASE-0009145 | ENDO | null | null | null | null | null | Y | null | null | 2023-09-01 | null | CN | US | null | 2023Q3 | null | Unknown | Consumer | Expedited | null |
233,366,882 | 23,336,688 | 2 | F | 20,231,222 | 20,231,225 | 2023-12-26 | 2023-12-27 | PER | null | US-AMGEN-USASP2023230316 | AMGEN | null | 75 | YR | E | M | Y | null | null | 2023-12-26 | null | PH | US | US | 2023Q4 | 75 | Male | Pharmacist | Periodic | null |
221,383,301 | 22,138,330 | 1 | I | 20,230,101 | 20,230,316 | 2023-03-26 | 2023-03-26 | 30DAY | null | US-GSK-US2023041322 | GLAXOSMITHKLINE | null | 61 | YR | null | F | Y | null | null | 2023-03-26 | null | CN | US | US | 2023Q1 | 61 | Female | Consumer | 30DAY | null |
223,730,261 | 22,373,026 | 1 | I | null | null | 2023-05-26 | 2023-05-26 | DIR | FDA-CDER-CTU-2023-39550 | null | FDA-CTU | null | 48 | YR | null | F | N | null | null | 2023-05-25 | N | HP | US | null | 2023Q2 | 48 | Female | Health professional | Direct | null |
1,923,611,719 | 19,236,117 | 19 | F | null | 20,231,031 | 2021-05-10 | 2023-11-07 | EXP | null | CA-GLENMARK PHARMACEUTICALS-2021GMK053805 | GLENMARK | Lee C, Wanson A, Frangou S, Chong D, Halpape K.. Opioid toxicity due to CNS depressant polypharmacy: A case report.. Ment Health Clin [Internet].. 2021;11 (2):70-4 | null | null | null | null | Y | null | null | 2023-11-07 | null | PH | CA | CA | 2023Q4 | null | Unknown | Pharmacist | Expedited | null |
222,177,841 | 22,217,784 | 1 | I | null | 20,210,327 | 2023-04-17 | 2023-04-17 | EXP | null | US-ROCHE-3236850 | ROCHE | null | null | null | null | M | Y | null | null | 2023-04-17 | null | CN | US | null | 2023Q2 | null | Male | Consumer | Expedited | null |
199,804,332 | 19,980,433 | 2 | F | null | 20,230,426 | 2021-10-21 | 2023-04-30 | EXP | null | GB-ROCHE-2939403 | ROCHE | null | null | null | E | F | Y | null | null | 2023-04-29 | null | CN | GB | null | 2023Q2 | null | Female | Consumer | Expedited | null |
231,328,141 | 23,132,814 | 1 | I | null | 20,231,026 | 2023-11-01 | 2023-11-01 | PER | null | US-ELI_LILLY_AND_COMPANY-US202310016636 | ELI LILLY AND CO | null | null | null | null | M | Y | null | null | 2023-11-01 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Periodic | null |
225,265,881 | 22,526,588 | 1 | I | null | null | 2023-06-05 | 2023-06-05 | DIR | FDA-CDER-CTU-2023-41442 | null | FDA-CTU | null | 60 | YR | null | F | N | null | null | 2023-06-05 | N | HP | US | null | 2023Q2 | 60 | Female | Health professional | Direct | null |
233,517,161 | 23,351,716 | 1 | I | null | 20,231,219 | 2023-12-29 | 2023-12-29 | EXP | null | AU-SAMSUNG BIOEPIS-SB-2023-34135 | SAMSUNG BIOEPIS | null | 12 | YR | T | F | Y | null | null | 2023-12-29 | null | MD | AU | AU | 2023Q4 | 12 | Female | Physician | Expedited | null |
216,221,254 | 21,622,125 | 4 | F | 20,221,113 | 20,230,202 | 2022-11-21 | 2023-02-09 | 30DAY | null | AR-PFIZER INC-PV202200103369 | PFIZER | null | 7 | YR | null | F | Y | null | null | 2023-02-09 | null | CN | AR | AR | 2023Q1 | 7 | Female | Consumer | 30DAY | null |
230,629,351 | 23,062,935 | 1 | I | 20,231,004 | 20,231,006 | 2023-10-13 | 2023-10-13 | EXP | null | NVSC2023IN218420 | NOVARTIS | null | 71 | YR | null | M | Y | null | null | 2023-10-13 | null | CN | IN | IN | 2023Q4 | 71 | Male | Consumer | Expedited | null |
230,115,832 | 23,011,583 | 2 | F | 20,220,601 | 20,231,116 | 2023-09-29 | 2023-11-21 | EXP | null | US-009507513-2304USA006900 | MERCK | null | 64 | YR | null | F | Y | null | null | 2023-11-21 | null | MD | US | US | 2023Q4 | 64 | Female | Physician | Expedited | null |
223,396,331 | 22,339,633 | 1 | I | 20,230,125 | 20,230,512 | 2023-05-18 | 2023-05-18 | EXP | null | FR-MYLANLABS-2023M1050723 | MYLAN | null | 47 | YR | null | M | Y | 98 | KG | 2023-05-18 | null | MD | FR | FR | 2023Q2 | 47 | Male | Physician | Expedited | 98 |
204,884,786 | 20,488,478 | 6 | F | 20,220,101 | 20,231,026 | 2022-02-18 | 2023-11-06 | EXP | null | US-INSMED, INC.-2021-10497-US | INSMED | null | null | null | null | F | Y | 64.399 | KG | 2023-11-06 | null | HP | US | US | 2023Q4 | null | Female | Health professional | Expedited | 64.4 |
218,528,891 | 21,852,889 | 1 | I | 20,180,101 | 20,220,711 | 2023-01-12 | 2023-01-12 | PER | null | US-APOTEX-2022AP010050 | APOTEX | Qin ES, Patel H, Montagnino J, Pham K, Lam NY.. Behavioral dysregulation exacerbated by intrathecal baclofen in an adolescent with severe traumatic brain injury. Journal of Pediatric Rehabilation Medicine. 2022;15:383-387 | 15 | YR | null | M | Y | null | null | 2023-01-12 | null | MD | US | US | 2023Q1 | 15 | Male | Physician | Periodic | null |
222,793,811 | 22,279,381 | 1 | I | null | 20,230,426 | 2023-05-03 | 2023-05-03 | PER | null | US-SA-2023SA134596 | SANOFI AVENTIS | null | null | null | A | F | Y | null | null | 2023-05-03 | null | MD | US | US | 2023Q2 | null | Female | Physician | Periodic | null |
205,522,442 | 20,552,244 | 2 | F | null | 20,230,322 | 2022-03-04 | 2023-03-29 | EXP | null | JP-GLAXOSMITHKLINE-JP2022039453 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-03-29 | null | MD | JP | JP | 2023Q1 | null | Unknown | Physician | Expedited | null |
218,430,571 | 21,843,057 | 1 | I | 20,220,101 | 20,230,106 | 2023-01-10 | 2023-01-10 | EXP | null | US-PFIZER INC-PV202300004079 | PFIZER | null | 76 | YR | null | M | Y | null | null | 2023-01-10 | null | CN | US | US | 2023Q1 | 76 | Male | Consumer | Expedited | null |
229,899,811 | 22,989,981 | 1 | I | null | 20,230,915 | 2023-09-27 | 2023-09-27 | PER | null | US-TEVA-2023-US-2928220 | TEVA | null | 43 | YR | A | F | Y | 90.72 | KG | 2023-09-27 | null | CN | US | US | 2023Q3 | 43 | Female | Consumer | Periodic | 90.7 |
232,544,071 | 23,254,407 | 1 | I | 20,230,101 | 20,230,905 | 2023-12-02 | 2023-12-02 | PER | null | US-IBSA PHARMA INC.-2023IBS000708 | IBSA INSTITUT BIOCHIMIQUE | null | null | null | null | null | Y | null | null | 2023-12-01 | null | CN | US | US | 2023Q4 | null | Unknown | Consumer | Periodic | null |
222,424,911 | 22,242,491 | 1 | I | 20,230,301 | 20,230,412 | 2023-04-22 | 2023-04-22 | PER | null | US-TEVA-2023-US-2878729 | TEVA | null | null | null | null | F | Y | null | null | 2023-04-22 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
230,911,952 | 23,091,195 | 2 | F | null | 20,231,013 | 2023-10-20 | 2023-10-23 | EXP | null | US-PFIZER INC-202300327794 | PFIZER | Dolan, B.. RECURRENT PNEUMONIA IN A PATIENT WITH PULMONARY CRYPTOCOCCUS. Chest. 2023;164(4)Supplemen:1388A-1389A | null | null | E | M | Y | null | null | 2023-10-23 | null | MD | US | US | 2023Q4 | null | Male | Physician | Expedited | null |
220,217,792 | 22,021,779 | 2 | F | 20,221,101 | 20,230,217 | 2023-02-22 | 2023-02-24 | EXP | null | JP-Eisai Medical Research-EC-2023-134311 | EISAI | null | 49 | YR | A | F | Y | 58 | KG | 2023-02-25 | null | MD | JP | JP | 2023Q1 | 49 | Female | Physician | Expedited | 58 |
228,533,901 | 22,853,390 | 1 | I | null | 20,230,809 | 2023-08-23 | 2023-08-23 | EXP | null | CA-AUROBINDO-AUR-APL-2023-054090 | AUROBINDO | Unknown.Unknown.Unknown | 71 | YR | null | F | Y | null | null | 2023-08-23 | null | HP | CA | CA | 2023Q3 | 71 | Female | Health professional | Expedited | null |
218,060,011 | 21,806,001 | 1 | I | null | 20,221,229 | 2023-01-02 | 2023-01-02 | EXP | null | US-GSK-US2022194796 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-01-02 | null | CN | US | US | 2023Q1 | null | Unknown | Consumer | Expedited | null |
219,902,171 | 21,990,217 | 1 | I | 20,230,209 | 20,230,210 | 2023-02-14 | 2023-02-14 | PER | null | US-PFIZER INC-202300063348 | PFIZER | null | 49 | YR | null | M | Y | null | null | 2023-02-14 | null | CN | US | US | 2023Q1 | 49 | Male | Consumer | Periodic | null |
217,036,913 | 21,703,691 | 3 | F | 20,221,110 | 20,230,105 | 2022-12-09 | 2023-01-08 | PER | null | US-JNJFOC-20221206595 | JOHNSON AND JOHNSON | null | 58 | YR | A | F | Y | null | null | 2023-01-08 | null | HP | US | US | 2023Q1 | 58 | Female | Health professional | Periodic | null |
214,673,564 | 21,467,356 | 4 | F | 20,220,901 | 20,230,817 | 2022-10-17 | 2023-08-18 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2022-107826 | BRISTOL MYERS SQUIBB | null | 69 | YR | E | M | Y | null | null | 2023-08-18 | null | CN | US | US | 2023Q3 | 69 | Male | Consumer | Periodic | null |
227,856,651 | 22,785,665 | 1 | I | null | 20,230,320 | 2023-08-04 | 2023-08-04 | PER | null | US-OTSUKA-2023_007364 | OTSUKA | null | null | null | null | F | Y | null | null | 2023-08-04 | null | PH | US | US | 2023Q3 | null | Female | Pharmacist | Periodic | null |
214,453,782 | 21,445,378 | 2 | F | null | 20,230,830 | 2022-10-12 | 2023-09-29 | PER | null | US-BAYER-2022A137043 | BAYER | null | 60 | YR | A | F | Y | null | null | 2023-09-29 | null | CN | US | US | 2023Q3 | 60 | Female | Consumer | Periodic | null |
219,977,342 | 21,997,734 | 2 | F | 20,230,110 | 20,230,222 | 2023-02-16 | 2023-02-27 | PER | null | US-UNITED THERAPEUTICS-UNT-2023-000937 | UNITED THERAPEUTICS | null | 70 | YR | null | F | Y | null | null | 2023-02-27 | null | HP | US | US | 2023Q1 | 70 | Female | Health professional | Periodic | null |
233,113,492 | 23,311,349 | 2 | F | null | 20,231,214 | 2023-12-19 | 2023-12-21 | PER | null | US-AMGEN-USASP2023224648 | AMGEN | null | null | null | null | null | Y | null | null | 2023-12-21 | null | HP | US | US | 2023Q4 | null | Unknown | Health professional | Periodic | null |
220,109,951 | 22,010,995 | 1 | I | null | 20,230,214 | 2023-02-20 | 2023-02-20 | PER | null | US-SA-2023SA052933 | SANOFI AVENTIS | null | null | null | A | F | Y | null | null | 2023-02-20 | null | MD | US | US | 2023Q1 | null | Female | Physician | Periodic | null |
149,530,076 | 14,953,007 | 6 | F | null | 20,231,121 | 2018-05-30 | 2023-11-30 | EXP | null | US-IMPAX LABORATORIES, INC-2018-IPXL-01795 | AMNEAL | null | null | null | null | F | Y | null | null | 2023-11-30 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Expedited | null |
219,333,961 | 21,933,396 | 1 | I | 20,220,101 | 20,221,028 | 2023-01-31 | 2023-01-31 | PER | null | US-AMGEN-USASP2022228496 | AMGEN | null | null | null | A | M | Y | null | null | 2023-01-31 | null | HP | US | US | 2023Q1 | null | Male | Health professional | Periodic | null |
215,445,796 | 21,544,579 | 6 | F | null | 20,230,913 | 2022-11-02 | 2023-09-19 | EXP | null | US-PFIZER INC-PV202200094691 | PFIZER | null | 82 | YR | null | F | Y | null | null | 2023-09-19 | null | MD | US | US | 2023Q3 | 82 | Female | Physician | Expedited | null |
223,955,181 | 22,395,518 | 1 | I | 20,230,306 | 20,230,525 | 2023-06-01 | 2023-06-01 | EXP | BE-FAMHP-DHH-N2023-120249 | BE-BAUSCH-BL-2023-008179 | BAUSCH AND LOMB | null | null | null | null | M | Y | 70 | KG | 2023-06-01 | null | PH | BE | BE | 2023Q2 | null | Male | Pharmacist | Expedited | 70 |
222,521,211 | 22,252,121 | 1 | I | 20,230,416 | 20,230,419 | 2023-04-25 | 2023-04-25 | PER | null | US-AMGEN-USASP2023069153 | AMGEN | null | 29 | YR | A | F | Y | null | null | 2023-04-25 | null | CN | US | US | 2023Q2 | 29 | Female | Consumer | Periodic | null |
231,985,282 | 23,198,528 | 2 | F | null | 20,231,115 | 2023-11-17 | 2023-11-21 | PER | null | NVSC2023US245003 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-11-21 | null | HP | US | US | 2023Q4 | null | Female | Health professional | Periodic | null |
218,478,611 | 21,847,861 | 1 | I | null | null | 2023-01-10 | 2023-01-10 | DIR | FDA-CDER-CTU-2023-2766 | null | FDA-CTU | null | null | null | null | F | N | null | null | 2023-01-09 | N | HP | US | null | 2023Q1 | null | Female | Health professional | Direct | null |
229,914,611 | 22,991,461 | 1 | I | 20,211,201 | 20,230,807 | 2023-09-27 | 2023-09-27 | EXP | null | GB-GLAXOSMITHKLINE-GBCH2023EME045810 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-09-27 | null | HP | GB | GB | 2023Q3 | null | Unknown | Health professional | Expedited | null |
229,027,961 | 22,902,796 | 1 | I | null | 20,230,829 | 2023-09-04 | 2023-09-04 | EXP | null | JP-GSK-JP2023119459 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-09-04 | null | MD | JP | JP | 2023Q3 | null | Unknown | Physician | Expedited | null |
218,970,221 | 21,897,022 | 1 | I | null | 20,230,109 | 2023-01-23 | 2023-01-23 | PER | null | US-EPICPHARMA-US-2023EPCSPO00052 | EPIC PHARM | null | 82 | YR | E | F | Y | null | null | 2023-01-23 | null | MD | US | US | 2023Q1 | 82 | Female | Physician | Periodic | null |
226,263,581 | 22,626,358 | 1 | I | 20,230,601 | 20,230,613 | 2023-06-21 | 2023-06-21 | EXP | null | JP-009507513-2306JPN001830J | MERCK | null | 39 | YR | null | F | Y | null | null | 2023-06-21 | null | MD | JP | JP | 2023Q2 | 39 | Female | Physician | Expedited | null |
226,446,181 | 22,644,618 | 1 | I | 20,230,403 | 20,230,614 | 2023-06-27 | 2023-06-27 | EXP | null | JP-AstraZeneca-2023A139170 | ASTRAZENECA | null | 68 | YR | null | F | Y | 46 | KG | 2023-06-27 | null | MD | JP | null | 2023Q2 | 68 | Female | Physician | Expedited | 46 |
160,950,243 | 16,095,024 | 3 | F | 20,110,626 | 20,230,406 | 2019-03-20 | 2023-04-12 | EXP | null | PL-SA-2019SA074232 | SANOFI AVENTIS | null | 8 | MON | I | M | Y | null | null | 2023-04-12 | null | MD | PL | PL | 2023Q2 | 0.67 | Male | Physician | Expedited | null |
220,664,891 | 22,066,489 | 1 | I | 20,230,225 | 20,230,227 | 2023-03-06 | 2023-03-06 | EXP | null | IN-TAKEDA-2023TUS022021 | TAKEDA | null | 51 | YR | null | F | Y | 70 | KG | 2023-03-06 | null | HP | IN | IN | 2023Q1 | 51 | Female | Health professional | Expedited | 70 |
223,503,351 | 22,350,335 | 1 | I | 20,230,512 | null | 2023-05-20 | 2023-05-20 | DIR | 660813 | null | FDA-CTU | null | 43 | YR | null | M | N | 96.75 | KG | 2023-05-20 | N | CN | US | null | 2023Q2 | 43 | Male | Consumer | Direct | 96.8 |
220,871,602 | 22,087,160 | 2 | F | 20,220,401 | 20,230,522 | 2023-03-13 | 2023-05-31 | PER | IT-002147023-NVSC2023IT041416 | IT-Shilpa Medicare Limited-SML-IT-2023-00279 | SHILPA MEDICARE | null | 67 | YR | E | M | Y | null | null | 2023-05-31 | null | MD | IT | IT | 2023Q2 | 67 | Male | Physician | Periodic | null |
222,068,663 | 22,206,866 | 3 | F | 20,230,301 | 20,230,619 | 2023-04-13 | 2023-06-28 | 30DAY | null | AR-PFIZER INC-PV202300059838 | PFIZER | null | 14 | YR | null | M | Y | null | null | 2023-06-28 | null | CN | AR | AR | 2023Q2 | 14 | Male | Consumer | 30DAY | null |
220,405,791 | 22,040,579 | 1 | I | null | 20,230,221 | 2023-02-27 | 2023-02-27 | PER | null | US-SA-2023SA064008 | SANOFI AVENTIS | null | null | null | C | M | Y | 18.1 | KG | 2023-02-27 | null | MD | US | US | 2023Q1 | null | Male | Physician | Periodic | 18.1 |
223,931,911 | 22,393,191 | 1 | I | 20,230,520 | 20,230,522 | 2023-06-01 | 2023-06-01 | PER | null | US-ELI_LILLY_AND_COMPANY-US202305015121 | ELI LILLY AND CO | null | 60 | YR | null | M | Y | null | null | 2023-06-01 | null | CN | US | US | 2023Q2 | 60 | Male | Consumer | Periodic | null |
218,448,311 | 21,844,831 | 1 | I | null | 20,221,221 | 2023-01-10 | 2023-01-10 | PER | null | US-LUNDBECK-DKLU3056284 | LUNDBECK | null | 13 | MON | null | M | Y | null | null | 2023-01-10 | null | CN | US | US | 2023Q1 | 1.08 | Male | Consumer | Periodic | null |
219,483,661 | 21,948,366 | 1 | I | 20,220,801 | 20,220,829 | 2023-02-03 | 2023-02-03 | EXP | null | US-RECORDATI-2022004133 | RECORDATI | null | null | null | null | null | Y | null | null | 2023-02-03 | null | CN | US | US | 2023Q1 | null | Unknown | Consumer | Expedited | null |
203,437,243 | 20,343,724 | 3 | F | 20,211,114 | 20,230,406 | 2022-01-18 | 2023-04-12 | PER | null | US-Blueprint Medicines Corporation-SP-US-2022-000032 | BLUEPRINT MEDICINES | null | 62 | YR | A | F | Y | null | null | 2023-04-12 | null | CN | US | US | 2023Q2 | 62 | Female | Consumer | Periodic | null |
219,683,661 | 21,968,366 | 1 | I | null | 20,230,206 | 2023-02-08 | 2023-02-08 | PER | null | US-PFIZER INC-PV202300024137 | PFIZER | null | 76 | YR | null | F | Y | null | null | 2023-02-08 | null | HP | US | US | 2023Q1 | 76 | Female | Health professional | Periodic | null |
230,828,531 | 23,082,853 | 1 | I | null | 20,231,005 | 2023-10-19 | 2023-10-19 | EXP | null | US-CIPLA LTD.-2023US06364 | CIPLA | Thayanantharajah T, Mohamed K, Parekh V, Khdeir O. Catecholamine-induced cardiomyopathy secondary to Phentermine and caffeine use. Chest. 2023;164 4S:694A | null | null | null | null | Y | null | null | 2023-10-19 | null | HP | US | US | 2023Q4 | null | Unknown | Health professional | Expedited | null |
227,888,961 | 22,788,896 | 1 | I | null | null | 2023-08-03 | 2023-08-03 | DIR | FDA-CDER-CTU-2023-56645 | null | FDA-CTU | null | 54 | YR | null | F | N | 108.86 | KG | 2023-08-03 | N | HP | US | null | 2023Q3 | 54 | Female | Health professional | Direct | 108.9 |
230,340,472 | 23,034,047 | 2 | F | 20,230,101 | 20,231,024 | 2023-10-05 | 2023-10-30 | EXP | null | JP-ABBVIE-5433975 | ABBVIE | null | 60 | YR | null | M | Y | null | null | 2023-10-30 | null | HP | JP | JP | 2023Q4 | 60 | Male | Health professional | Expedited | null |
233,186,351 | 23,318,635 | 1 | I | 20,231,211 | 20,231,211 | 2023-12-20 | 2023-12-20 | PER | null | US-BIOGEN-2023BI01240798 | BIOGEN | null | 34 | YR | null | M | Y | null | null | 2023-12-20 | null | CN | US | US | 2023Q4 | 34 | Male | Consumer | Periodic | null |
217,918,063 | 21,791,806 | 3 | F | null | 20,230,111 | 2022-12-29 | 2023-01-13 | EXP | null | TW-SA-2022SA522173 | SANOFI AVENTIS | null | null | null | A | F | Y | null | null | 2023-01-13 | null | MD | TW | TW | 2023Q1 | null | Female | Physician | Expedited | null |
158,919,076 | 15,891,907 | 6 | F | 20,190,301 | 20,230,202 | 2019-01-30 | 2023-02-09 | EXP | null | US-SHIRE-US201902965 | TAKEDA | null | 54 | YR | null | M | Y | null | null | 2023-02-09 | null | MD | US | US | 2023Q1 | 54 | Male | Physician | Expedited | null |
231,932,541 | 23,193,254 | 1 | I | 20,230,901 | 20,231,106 | 2023-11-16 | 2023-11-16 | EXP | null | BR-ELI_LILLY_AND_COMPANY-BR202311008375 | ELI LILLY AND CO | null | 48 | YR | null | F | Y | null | null | 2023-11-16 | null | CN | DE | BR | 2023Q4 | 48 | Female | Consumer | Expedited | null |
226,974,732 | 22,697,473 | 2 | F | 20,190,101 | 20,230,807 | 2023-07-12 | 2023-08-14 | EXP | FR-AFSSAPS-AVLL2023000089 | FR-MYLANLABS-2023M1073456 | MYLAN | null | 31 | YR | null | F | Y | null | null | 2023-08-14 | null | PH | FR | FR | 2023Q3 | 31 | Female | Pharmacist | Expedited | null |
230,872,891 | 23,087,289 | 1 | I | null | 20,230,623 | 2023-10-20 | 2023-10-20 | EXP | null | US-ENDO PHARMACEUTICALS INC-2023-003924 | ENDO | null | null | null | null | M | Y | null | null | 2023-10-20 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Expedited | null |
208,431,562 | 20,843,156 | 2 | F | null | 20,221,014 | 2022-05-18 | 2023-05-24 | PER | null | US-Bion-010672 | BIONPHARMA | null | null | null | A | F | Y | null | null | 2023-05-24 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
164,617,836 | 16,461,783 | 6 | F | null | 20,230,207 | 2019-06-21 | 2023-02-14 | EXP | null | US-GLAXOSMITHKLINE-US2019GSK110910 | PERRIGO | null | null | null | null | null | Y | null | null | 2023-02-14 | null | CN | US | US | 2023Q1 | null | Unknown | Consumer | Expedited | null |
227,573,791 | 22,757,379 | 1 | I | 20,230,701 | 20,230,721 | 2023-07-27 | 2023-07-27 | EXP | null | AR-PFIZER INC-PV202300128173 | PFIZER | null | 74 | YR | null | M | Y | null | null | 2023-07-27 | null | CN | AR | AR | 2023Q3 | 74 | Male | Consumer | Expedited | null |
228,230,651 | 22,823,065 | 1 | I | null | 20,230,809 | 2023-08-15 | 2023-08-15 | EXP | null | US-AstraZeneca-2023A182999 | ASTRAZENECA | null | null | null | null | F | Y | null | null | 2023-08-15 | null | PH | US | null | 2023Q3 | null | Female | Pharmacist | Expedited | null |
226,422,041 | 22,642,204 | 1 | I | null | 20,230,619 | 2023-06-26 | 2023-06-26 | EXP | null | CN-ELI_LILLY_AND_COMPANY-CN202306013276 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-06-26 | null | CN | CN | CN | 2023Q2 | null | Female | Consumer | Expedited | null |
220,456,361 | 22,045,636 | 1 | I | 20,230,220 | 20,230,220 | 2023-02-28 | 2023-02-28 | PER | null | US-AMGEN-USASP2023033470 | AMGEN | null | 80 | YR | E | M | Y | null | null | 2023-02-28 | null | PH | US | US | 2023Q1 | 80 | Male | Pharmacist | Periodic | null |
228,139,981 | 22,813,998 | 1 | I | 20,230,601 | 20,230,808 | 2023-08-11 | 2023-08-11 | EXP | null | NVSC2023SK173654 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-08-11 | null | MD | SK | SK | 2023Q3 | null | Female | Physician | Expedited | null |
208,899,575 | 20,889,957 | 5 | F | null | 20,230,423 | 2022-05-30 | 2023-04-28 | EXP | null | NVSC2022EG121519 | NOVARTIS | null | null | null | null | M | Y | 3.2 | KG | 2023-04-28 | null | CN | EG | EG | 2023Q2 | null | Male | Consumer | Expedited | 3.2 |
227,883,781 | 22,788,378 | 1 | I | null | 20,230,801 | 2023-08-04 | 2023-08-04 | PER | null | US-SA-2023SA236903 | SANOFI AVENTIS | null | 60 | YR | A | F | Y | null | null | 2023-08-04 | null | CN | US | US | 2023Q3 | 60 | Female | Consumer | Periodic | null |
218,714,271 | 21,871,427 | 1 | I | 20,230,111 | 20,230,111 | 2023-01-17 | 2023-01-17 | PER | null | US-SA-2023SA014195 | SANOFI AVENTIS | null | 55 | YR | A | F | Y | null | null | 2023-01-17 | null | PH | US | US | 2023Q1 | 55 | Female | Pharmacist | Periodic | null |
231,525,871 | 23,152,587 | 1 | I | 20,231,019 | 20,231,102 | 2023-11-07 | 2023-11-07 | EXP | null | NVSC2023CN236877 | NOVARTIS | null | 56 | YR | null | M | Y | 52 | KG | 2023-11-07 | null | HP | CN | CN | 2023Q4 | 56 | Male | Health professional | Expedited | 52 |
222,167,261 | 22,216,726 | 1 | I | null | 20,230,407 | 2023-04-17 | 2023-04-17 | EXP | null | NL-AUROBINDO-AUR-APL-2023-030492 | AUROBINDO | null | null | null | E | F | Y | 76.1 | KG | 2023-04-17 | null | MD | NL | NL | 2023Q2 | null | Female | Physician | Expedited | 76.1 |
222,160,912 | 22,216,091 | 2 | F | 20,230,320 | 20,230,503 | 2023-04-17 | 2023-05-22 | PER | null | CA-TOLMAR, INC.-23CA039688 | TOLMAR | null | 73 | YR | null | M | Y | null | null | 2023-05-22 | null | PH | CA | CA | 2023Q2 | 73 | Male | Pharmacist | Periodic | null |
231,322,281 | 23,132,228 | 1 | I | null | 20,231,026 | 2023-11-01 | 2023-11-01 | EXP | null | CA-ROCHE-3446945 | ROCHE | null | 40 | YR | null | M | Y | null | null | 2023-11-01 | null | HP | CA | null | 2023Q4 | 40 | Male | Health professional | Expedited | null |
218,105,831 | 21,810,583 | 1 | I | 20,221,215 | 20,221,223 | 2023-01-03 | 2023-01-03 | PER | null | US-BAYER-2022A174583 | BAYER | null | 84 | YR | E | M | Y | null | null | 2023-01-03 | null | CN | US | US | 2023Q1 | 84 | Male | Consumer | Periodic | null |
213,276,073 | 21,327,607 | 3 | F | null | 20,230,309 | 2022-09-13 | 2023-03-17 | EXP | null | CA-SAMSUNG BIOEPIS-SB-2022-22512 | SAMSUNG BIOEPIS | null | 67 | YR | E | M | Y | 115 | KG | 2023-03-17 | null | HP | CA | CA | 2023Q1 | 67 | Male | Health professional | Expedited | 115 |
222,288,981 | 22,228,898 | 1 | I | 20,230,414 | null | 2023-04-18 | 2023-04-18 | DIR | FDA-CDER-CTU-2023-28938 | null | FDA-CTU | null | 49 | YR | null | F | N | null | null | 2023-04-18 | Y | PH | US | null | 2023Q2 | 49 | Female | Pharmacist | Direct | null |
232,273,472 | 23,227,347 | 2 | F | 20,180,601 | 20,231,130 | 2023-11-24 | 2023-12-07 | EXP | null | CA-PFIZER INC-2018246651 | PFIZER | null | 53 | YR | null | F | Y | null | null | 2023-12-07 | null | CN | CA | CA | 2023Q4 | 53 | Female | Consumer | Expedited | null |
229,053,621 | 22,905,362 | 1 | I | null | 20,230,828 | 2023-09-05 | 2023-09-05 | PER | null | US-SA-2023SA266850 | SANOFI AVENTIS | null | 57 | YR | A | F | Y | null | null | 2023-09-05 | null | MD | US | US | 2023Q3 | 57 | Female | Physician | Periodic | null |
221,229,052 | 22,122,905 | 2 | F | null | 20,230,616 | 2023-03-22 | 2023-06-28 | EXP | null | BR-CELLTRION INC.-2023BR005907 | CELLTRION | null | null | null | null | null | Y | null | null | 2023-06-29 | null | CN | BR | BR | 2023Q2 | null | Unknown | Consumer | Expedited | null |
232,920,171 | 23,292,017 | 1 | I | null | 20,230,123 | 2023-12-13 | 2023-12-13 | PER | null | US-ABBVIE-2302543US | ABBVIE | null | null | null | null | null | Y | null | null | 2023-12-13 | null | CN | US | US | 2023Q4 | null | Unknown | Consumer | Periodic | null |
228,182,772 | 22,818,277 | 2 | F | 20,230,724 | 20,230,906 | 2023-08-14 | 2023-09-27 | PER | null | US-TOLMAR, INC.-23US042220 | TOLMAR | null | 86 | YR | null | M | Y | null | null | 2023-09-27 | null | PH | US | US | 2023Q3 | 86 | Male | Pharmacist | Periodic | null |
218,579,122 | 21,857,912 | 2 | F | 20,200,831 | 20,230,406 | 2023-01-13 | 2023-04-06 | PER | null | US-BIOGEN-2020BI00921988 | BIOGEN | null | 44 | YR | null | F | Y | null | null | 2023-04-06 | null | CN | US | US | 2023Q2 | 44 | Female | Consumer | Periodic | null |
224,000,821 | 22,400,082 | 1 | I | 20,230,527 | 20,230,530 | 2023-06-02 | 2023-06-02 | EXP | null | CN-AstraZeneca-2023A125710 | ASTRAZENECA | null | 64 | YR | null | M | Y | 65 | KG | 2023-06-02 | null | MD | CN | null | 2023Q2 | 64 | Male | Physician | Expedited | 65 |
226,712,912 | 22,671,291 | 2 | F | 20,230,626 | 20,230,809 | 2023-07-05 | 2023-08-21 | PER | null | US-AMGEN-USASP2023112349 | AMGEN | null | 64 | YR | A | F | Y | 81 | KG | 2023-08-21 | null | PH | US | US | 2023Q3 | 64 | Female | Pharmacist | Periodic | 81 |
218,693,281 | 21,869,328 | 1 | I | null | 20,230,109 | 2023-01-17 | 2023-01-17 | PER | null | US-ELI_LILLY_AND_COMPANY-US202301005712 | ELI LILLY AND CO | null | null | null | null | M | Y | null | null | 2023-01-17 | null | CN | US | US | 2023Q1 | null | Male | Consumer | Periodic | null |
220,043,541 | 22,004,354 | 1 | I | 20,230,101 | 20,230,214 | 2023-02-17 | 2023-02-17 | EXP | null | US-SA-2023SA053579 | SANOFI AVENTIS | null | 63 | YR | A | F | Y | null | null | 2023-02-17 | null | MD | US | US | 2023Q1 | 63 | Female | Physician | Expedited | null |
232,331,061 | 23,233,106 | 1 | I | 20,231,101 | 20,231,120 | 2023-11-28 | 2023-11-28 | PER | null | US-AMGEN-USASP2023211676 | AMGEN | null | null | null | null | M | Y | null | null | 2023-11-28 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Periodic | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.